Intra-Cellular Therapies (ITCI) Tops Q4 Loss Expectations
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($0.67), $0.23 better than the analyst estimate of ($0.90). Revenue for the quarter came in at $30.66 million versus the consensus estimate of $60 thousand.
For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: BlackBerry (BB) Reports In-Line Q1 EPS
- Nike profit, sales beat estimates on strong demand from Americans leaving lockdown
- Carnival Corp. (CCL) sees adjusted net loss of $2 billion for Q2, says customer deposits increased
Create E-mail Alert Related CategoriesEarnings
Related EntitiesThe Children's Investment Fund (TCI), Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!